Skip to content

Florida / New York
Facebook Twitter Linkedin
  • ADVERTISE
  • CONTACT
  • ADVERTISE
  • CONTACT

Medical Device News Magazine

A Publication for the Practicing Medical Specialist, Industry Executive & Investor

  • HOME
    • ABOUT
    • PRESS RELEASES
      • EDITORIAL
  • MEDICAL DEVICES
    • BIOTECHNOLOGY
    • CLINICAL TRIALS
  • INDUSTRY BYLINES
  • OTHER NEWS
    • EXECUTIVES
    • HOSPITALS
    • IMAGING
    • MERGERS/ACQUISITIONS
    • FUNDING
    • FDA
    • MARKET REPORTS
    • HEALTHCARE BUSINESS
    • HEALTHCARE PROFESSIONALS
    • CAREERS
  • HEALTH
    • ARTICLES
  • HOME
    • ABOUT
    • PRESS RELEASES
      • EDITORIAL
  • MEDICAL DEVICES
    • BIOTECHNOLOGY
    • CLINICAL TRIALS
  • INDUSTRY BYLINES
  • OTHER NEWS
    • EXECUTIVES
    • HOSPITALS
    • IMAGING
    • MERGERS/ACQUISITIONS
    • FUNDING
    • FDA
    • MARKET REPORTS
    • HEALTHCARE BUSINESS
    • HEALTHCARE PROFESSIONALS
    • CAREERS
  • HEALTH
    • ARTICLES

NST002 Phase IIa Study (ALS) Promising Results Continue Reports NeuroSense

  • Post author:Medical Device News Magazine
  • Post published:November 18, 2020
  • Post category:CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

The study is set to be completed in January of 2021, following 12-months dosing.

Continue ReadingNST002 Phase IIa Study (ALS) Promising Results Continue Reports NeuroSense
  • Go to the previous page
  • 1
  • 2
  • 3
  • 4
  • 5

Contact Us Today!

  • Email: advmdn@infomeddnews.com
  • Florida | New York
  • HOME
  • ABOUT
  • ADVERTISE
  • PRIVACY STATEMENT
  • CONTACT
  • COOKIE POLICY
  • HOME
  • ABOUT
  • ADVERTISE
  • PRIVACY STATEMENT
  • CONTACT
  • COOKIE POLICY

Copyright 2025 | All Rights Reserved | Medical Device News Magazine, is a Division of PTM Healthcare Marketing, Inc.